Neurocrine Biosciences Inc (NBIX NASDAQ) stock market data APIs
$144.4111
-1.08(-0.7%)
as of November 14, 2025
Try our APIs with
free plan!
Neurocrine Biosciences Inc Financial Data Overview
Price chart is built with
Anychart
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Prev. Close
144.4111
Open
143.3348
High
145.9324
Low
143.3348
52 wk Range
84.23-157.67
Market Cap
14 443 M
P/E Ratio
34.327
Shares Outstanding
99 706 K
Revenue
2 683 M
EPS
2.17
Beta
0.28
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Neurocrine Biosciences Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Neurocrine Biosciences Inc data using free add-ons & libraries
Get Neurocrine Biosciences Inc Fundamental Data
Neurocrine Biosciences Inc Fundamental data includes:
- Net Revenue: 2 683 M
- EBITDA: 570 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-30
- EPS/Forecast: 2.09
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Neurocrine Biosciences Inc News
New
Assessing Neurocrine Biosciences (NBIX) Valuation After Recent Share Price Momentum
Neurocrine Biosciences (NBIX) has seen meaningful movement over the past month, drawing investor attention to its latest performance metrics. Shares have advanced 7% in the past month and are up 17% o...
Assessing Neurocrine Biosciences After Stock Rises 7.8% and Partnership Expansion News
If you have ever wondered whether Neurocrine Biosciences is currently trading for a bargain or riding high on hype, you are in the right place. The stock has made notable moves recently, rising 2.9% o...
Neurocrine Biosciences to Present at Upcoming Investor Conferences
SAN DIEGO, Nov. 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences:(PRNewsf...
Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice
Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
